Lindy Biosciences

Executive Summary

Lindy Biosciences is a privately held biotechnology company headquartered in Cambridge, MA, founded in 2021 with a focus on transforming biotherapeutic administration. Its proprietary Microglassification™ platform is a dehydration technology that creates highly concentrated protein suspensions, enabling subcutaneous delivery of high-dose biologics that traditionally require intravenous infusion. This patient-centric approach aims to shift treatment from clinical settings to convenient at-home injections, improving patient comfort, adherence, and quality of life. By addressing the volume and viscosity limitations of conventional formulations, Lindy's technology has the potential to unlock subcutaneous delivery for a broad range of protein-based therapies, including monoclonal antibodies and fusion proteins. Lindy operates in the drug delivery segment, targeting a significant unmet need in chronic disease management where frequent IV infusions impose a burden on patients and healthcare systems. The company's early-stage platform has the potential to partner with biopharma firms seeking to differentiate their biologics through enhanced delivery. While Lindy has not publicly disclosed funding rounds or pipeline programs, its technology is positioned to address a multi-billion-dollar market opportunity. Key near-term milestones include securing series financing, establishing preclinical proof-of-concept partnerships, and advancing toward an IND filing for a lead indication. Success will depend on demonstrating the platform's versatility, scalability, and clinical benefit in vivo.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing70% success
• 2027Pharmaceutical Partnership for Microglassification Platform40% success
• Q4 2026Publication of Preclinical In Vivo Data for Lead Candidate80% success